search
Back to results

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia (SAPPHIRE)

Primary Purpose

Chronic Kidney Disease

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Verinurad
Allopurinol
Placebo for Verinurad
Placebo for Allopurinol
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Kidney Disease focused on measuring Chronic Kidney Disease

Eligibility Criteria

18 Years - 130 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The subject has given written informed consent prior to any mandatory study specific procedures, sampling, and analyses, and is able to understand and comply with all study procedures
  • Adult Patient ≥18 years of age with CKD for >3 months.
  • Patients with background standard of care treatment for albuminuria and/or T2DM and treated according to locally recognised guidelines. Therapy optimised and stable for ≥4 weeks before study entry and including an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, unless justified.
  • If treated with a sodium-glucose transport protein (SGLT2) inhibitor, stable dose for ≥4 weeks before randomisation.
  • Meeting screening criteria for sUA and eGFR (Visit 2): sUA ≥6.0 mg/dL. ∙ eGFR ≥25 mL/min/1.73 m2 Chronic Kidney Disease Epidemiology Collaboration
  • UACR between 30 mg/g and 5000 mg/g.
  • Female patients: Negative pregnancy test for childbearing potential. 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception during the study and 4 weeks after the last dose of study treatment.

Exclusion Criteria:

  • Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or anti-neutrophil cytoplasmic antibody associated vasculitis (granulomatosis with polyangiitis [Wegener's granulomatosis], microscopic polyangiitis, or eosinophilic granulomatosis with polyangiitis [Churg-Strauss syndrome]).
  • History of renal transplantation
  • Known carrier of the Human Leukocyte Antigen-B *58:01 allele.
  • Patients diagnosed with tumor lysis syndrome or Lesch-Nyhan syndrome
  • Patients who in the opinion of investigator are unable to perform the patients' tasks associated with the protocol or Presence of any condition which, places the patient at undue risk or potentially jeopardises the quality of the data to be generated
  • History of stroke, myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft in the past 6 months
  • Uncontrolled hypertension presenting with systolic blood pressure >180 mm Hg and/or diastolic blood pressure >100 mm Hg
  • Diagnosed with heart failure and New York Heart Association Functional Classification Class IV at the time of randomisation
  • QT interval corrected by the Fridericia formula >470 msec; patients diagnosed with long QT syndrome; patients with a family history of long QT syndrome.
  • Subjects with severe hepatic impairment, as judged by the investigator, of Child-Pugh Class C (decompensated cirrhosis), or with major cirrhosis complications (eg, hepatorenal syndrome)
  • Receiving cytotoxic or immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment
  • Treated with any drug for hyperuricaemia in the 6 months preceding randomisation.
  • Dose of ACEi, ARBs, fenofibrate, guaifenesin, or SGLT2 inhibitors changed within 4 weeks of randomisation or further dose titration expected after randomization

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

High Dose

Intermediate Dose

Low Dose

Allopurinol alone (0/300 mg)

Placebo (0/0 mg)

Arm Description

High Dose (mg) (verinurad/allopurinol) Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 12/300

Intermediate Dose (mg) verinurad/allopurinol Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 7.5/300

Low Dose (mg) verinurad/allopurinol Step 1 - titration_3/100 Step 2 - titration_3/200 Step 3 - target dose_3/300. As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at Visit 9.

Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose_0/300

Placebo (mg) in 3 steps_0/0

Outcomes

Primary Outcome Measures

Urinary Albumin to Creatinine Ratio (uACR) (mg/g) Change From Baseline at 6 Months (Visit 8), Repeated Measures Mixed Model (MMRM)
Analyses of change from baseline in uACR at 6 months (Visit 8) focused on: High dose vs Placebo High dose and Inter. dose combined vs Allopurinol alone Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo For High dose and Inter. dose combined the 2 categories merged forming 1 new temporary category.

Secondary Outcome Measures

Urinary Albumin to Creatinine Ratio (uACR) (mg/g) Change From Baseline at 12 Months (Visit 10), Repeated Measures Mixed Model (MMRM)
Change from baseline in uACR at 12 months (Visit 10) for comparison of Switch dose protocol version 5.0 (PA5) versus double-capsule Placebo. The statistical model applied was an MMRM, which was basically the same as the one applied in the primary analysis but adjusted for a 12 month horizon and adapted to the double-capsule regimen from Visit 9 on.
Serum Uric Acid (sUA) (mg/dL) Change From Baseline at 6 Months (Visit 8), Repeated Measures Mixed Model (MMRM)
Change from baseline in sUA at 6 months (Visit 8), there were 7 comparisons requested for each endpoint, namely: High dose vs Placebo Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo.
Serum Uric Acid (sUA) Change From Baseline at 12 Months (Visit 10), Repeated Measures Mixed Model (MMRM)
Change from baseline in sUA at 12 months (Visit 10) for comparison of Switch dose protocol version 5.0 (PA5) versus double-capsule Placebo.
Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM)
Change from baseline in eGFR at 6 months (Visit 8), there were 7 comparisons requested for this endpoint, namely: High dose vs Placebo Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo.
Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 12 Months (Visit 10)
Change from baseline in eGFR at 12 months (Visit 10) for the following treatments: High Dose Inter. Dose Low Dose (a) Switch Dose protocol version 5.0 (PA5) (b) Allopurinol Placebo Subjects that switched from Verinurad 3 mg to Verinurad 24 mg at Visit 9 are not included in this group for Visit 10. Contains all subjects randomized to the low dose group that later switched to Verinurad 24 mg plus Allopurinol 300 mg.
S-creatinine (mg/dL) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM)
Change from baseline in S-creatinine at 6 months (Visit 8), there were 7 comparisons requested for this endpoint, namely: High dose vs Placebo Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo.
S-creatinine (mg/dL) Change From Baseline at 12 Months (Visit 10)
Change from baseline in S-creatinine at 12 months (Visit 10) for the following treatments: High Dose Inter. Dose Low Dose (a) Switch Dose protocol version 5.0 (PA5) (b) Allopurinol Placebo Subjects that switched from Verinurad 3 mg to Verinurad 24 mg at Visit 9 are not included in this group for Visit 10. Contains all subjects randomized to the low dose group that later switched to Verinurad 24 mg plus Allopurinol 300 mg.
P-cystatin C (mg/L) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM)
Change from baseline in P-cystatin C at 6 months (Visit 8), there were 7 comparisons requested for this endpoint, namely: High dose vs Placebo Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo.
P-cystatin C (mg/L) Change From Baseline at 12 Months (Visit 10)
Change from baseline in S-creatinine at 12 months (Visit 10) for the following treatments: High Dose Inter. Dose Low Dose (a) Switch Dose protocol version 5.0 (PA5) (b) Allopurinol Placebo Subjects that switched from Verinurad 3 mg to Verinurad 24 mg at Visit 9 are not included in this group for Visit 10. Contains all subjects randomized to the low dose group that later switched to Verinurad 24 mg plus Allopurinol 300 mg.

Full Information

First Posted
May 30, 2019
Last Updated
February 1, 2023
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT03990363
Brief Title
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
Acronym
SAPPHIRE
Official Title
A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients With Chronic KIdney Disease and Hyperuricaemia
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
July 23, 2019 (Actual)
Primary Completion Date
November 22, 2021 (Actual)
Study Completion Date
November 22, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this clinical research study is to establish the dose of verinurad combined with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in urinary albumin to creatinine ratio (UACR) at 6 months.
Detailed Description
Evidence shows independent associations between hyperuricaemia and the risk of hypertension, myocardial infarction, chronic kidney disease (CKD), type 2 diabetes, heart failure, and metabolic syndrome, including obesity Furthermore, gout, an inflammatory arthritis caused by deposition of monosodium urate crystals in joints, is associated with an increased risk of all-cause death, as well as cardiovascular (CV) death. Hyperuricaemia is a prerequisite for development of gout, thus linking high levels of sUA to gout and to poor outcomes. However, the causal relationship between hyperuricaemia / gout and the aforementioned diseases and outcomes remains to be proven. Uric acid transporter 1 (URAT1) is responsible for reabsorption of uric acid (UA in the proximal tubule. Inhibition of URAT1 results in increased urinary excretion of UA. Verinurad (RDEA3170) is a novel URAT1 inhibitor in Phase 2 development for chronic kidney disease and heart failure. Verinurad combined with the xanthine oxidase (XO)inhibitor (XOI) febuxostat or allopurinol has been shown to lower sUA in patients with recurrent gout in Phase 2 studies by up to 80%.. The primary objective of this study is to assess the effects of treatment with verinurad and allopurinol, allopurinol alone, and placebo on UACR at 6 months. In this study, change in UACR at 6 months of treatment is the primary endpoint for the efficacy evaluation of treatment with the combination of verinurad and allopurinol vs. placebo. A key secondary objective is evaluation of verinurad plus allopurinol on the reduction in UACR at 12 months. Further, standard safety parameters such as adverse event (AEs), serious adverse event (SAEs), and laboratory evaluations will be employed to assess the safety profile of the study drugs. Verinurad, allopurinol and oxypurinol plasma concentrations over time will also be measured. The study will recruit patients with Chronic Kidney Disease and Hyperuricaemia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Kidney Disease
Keywords
Chronic Kidney Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
861 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High Dose
Arm Type
Experimental
Arm Description
High Dose (mg) (verinurad/allopurinol) Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 12/300
Arm Title
Intermediate Dose
Arm Type
Experimental
Arm Description
Intermediate Dose (mg) verinurad/allopurinol Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 7.5/300
Arm Title
Low Dose
Arm Type
Experimental
Arm Description
Low Dose (mg) verinurad/allopurinol Step 1 - titration_3/100 Step 2 - titration_3/200 Step 3 - target dose_3/300. As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at Visit 9.
Arm Title
Allopurinol alone (0/300 mg)
Arm Type
Experimental
Arm Description
Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose_0/300
Arm Title
Placebo (0/0 mg)
Arm Type
Placebo Comparator
Arm Description
Placebo (mg) in 3 steps_0/0
Intervention Type
Drug
Intervention Name(s)
Verinurad
Intervention Description
Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad. As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9
Intervention Type
Drug
Intervention Name(s)
Allopurinol
Intervention Description
Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol
Intervention Type
Drug
Intervention Name(s)
Placebo for Verinurad
Other Intervention Name(s)
Placebo
Intervention Description
Matching Capsule
Intervention Type
Drug
Intervention Name(s)
Placebo for Allopurinol
Other Intervention Name(s)
Placebo
Intervention Description
Matching tablet
Primary Outcome Measure Information:
Title
Urinary Albumin to Creatinine Ratio (uACR) (mg/g) Change From Baseline at 6 Months (Visit 8), Repeated Measures Mixed Model (MMRM)
Description
Analyses of change from baseline in uACR at 6 months (Visit 8) focused on: High dose vs Placebo High dose and Inter. dose combined vs Allopurinol alone Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo For High dose and Inter. dose combined the 2 categories merged forming 1 new temporary category.
Time Frame
Baseline to 9 months (Visit 9); analysis at 6 months (Visit 8)
Secondary Outcome Measure Information:
Title
Urinary Albumin to Creatinine Ratio (uACR) (mg/g) Change From Baseline at 12 Months (Visit 10), Repeated Measures Mixed Model (MMRM)
Description
Change from baseline in uACR at 12 months (Visit 10) for comparison of Switch dose protocol version 5.0 (PA5) versus double-capsule Placebo. The statistical model applied was an MMRM, which was basically the same as the one applied in the primary analysis but adjusted for a 12 month horizon and adapted to the double-capsule regimen from Visit 9 on.
Time Frame
Baseline to 12 months (Visit 10); analysis at 12 months (Visit 10)
Title
Serum Uric Acid (sUA) (mg/dL) Change From Baseline at 6 Months (Visit 8), Repeated Measures Mixed Model (MMRM)
Description
Change from baseline in sUA at 6 months (Visit 8), there were 7 comparisons requested for each endpoint, namely: High dose vs Placebo Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo.
Time Frame
Baseline to 9 months (Visit 9); analysis at 6 months (Visit 8)
Title
Serum Uric Acid (sUA) Change From Baseline at 12 Months (Visit 10), Repeated Measures Mixed Model (MMRM)
Description
Change from baseline in sUA at 12 months (Visit 10) for comparison of Switch dose protocol version 5.0 (PA5) versus double-capsule Placebo.
Time Frame
Baseline to 12 months (Visit 10); analysis at 12 months (Visit 10)
Title
Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM)
Description
Change from baseline in eGFR at 6 months (Visit 8), there were 7 comparisons requested for this endpoint, namely: High dose vs Placebo Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo.
Time Frame
Baseline to 9 months (Visit 9); analysis at 6 months (Visit 8)
Title
Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 12 Months (Visit 10)
Description
Change from baseline in eGFR at 12 months (Visit 10) for the following treatments: High Dose Inter. Dose Low Dose (a) Switch Dose protocol version 5.0 (PA5) (b) Allopurinol Placebo Subjects that switched from Verinurad 3 mg to Verinurad 24 mg at Visit 9 are not included in this group for Visit 10. Contains all subjects randomized to the low dose group that later switched to Verinurad 24 mg plus Allopurinol 300 mg.
Time Frame
Change from baseline to 12 months (Visit 10)
Title
S-creatinine (mg/dL) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM)
Description
Change from baseline in S-creatinine at 6 months (Visit 8), there were 7 comparisons requested for this endpoint, namely: High dose vs Placebo Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo.
Time Frame
Baseline to 9 months (Visit 9); analysis at 6 months (Visit 8)
Title
S-creatinine (mg/dL) Change From Baseline at 12 Months (Visit 10)
Description
Change from baseline in S-creatinine at 12 months (Visit 10) for the following treatments: High Dose Inter. Dose Low Dose (a) Switch Dose protocol version 5.0 (PA5) (b) Allopurinol Placebo Subjects that switched from Verinurad 3 mg to Verinurad 24 mg at Visit 9 are not included in this group for Visit 10. Contains all subjects randomized to the low dose group that later switched to Verinurad 24 mg plus Allopurinol 300 mg.
Time Frame
Change from baseline to 12 months (Visit 10)
Title
P-cystatin C (mg/L) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM)
Description
Change from baseline in P-cystatin C at 6 months (Visit 8), there were 7 comparisons requested for this endpoint, namely: High dose vs Placebo Inter. dose vs Placebo Low dose vs Placebo High dose vs Allopurinol Inter. dose vs Allopurinol Low dose vs Allopurinol Allopurinol vs Placebo.
Time Frame
Baseline to 9 months (Visit 9); analysis at 6 months (Visit 8)
Title
P-cystatin C (mg/L) Change From Baseline at 12 Months (Visit 10)
Description
Change from baseline in S-creatinine at 12 months (Visit 10) for the following treatments: High Dose Inter. Dose Low Dose (a) Switch Dose protocol version 5.0 (PA5) (b) Allopurinol Placebo Subjects that switched from Verinurad 3 mg to Verinurad 24 mg at Visit 9 are not included in this group for Visit 10. Contains all subjects randomized to the low dose group that later switched to Verinurad 24 mg plus Allopurinol 300 mg.
Time Frame
Change from baseline to 12 months (Visit 10)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
130 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The subject has given written informed consent prior to any mandatory study specific procedures, sampling, and analyses, and is able to understand and comply with all study procedures Adult Patient ≥18 years of age with CKD for >3 months. Patients with background standard of care treatment for albuminuria and/or T2DM and treated according to locally recognised guidelines. Therapy optimised and stable for ≥4 weeks before study entry and including an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, unless justified. If treated with a sodium-glucose transport protein (SGLT2) inhibitor, stable dose for ≥4 weeks before randomisation. Meeting screening criteria for sUA and eGFR (Visit 2): sUA ≥6.0 mg/dL. ∙ eGFR ≥25 mL/min/1.73 m2 Chronic Kidney Disease Epidemiology Collaboration UACR between 30 mg/g and 5000 mg/g. Female patients: Negative pregnancy test for childbearing potential. 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception during the study and 4 weeks after the last dose of study treatment. Exclusion Criteria: Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or anti-neutrophil cytoplasmic antibody associated vasculitis (granulomatosis with polyangiitis [Wegener's granulomatosis], microscopic polyangiitis, or eosinophilic granulomatosis with polyangiitis [Churg-Strauss syndrome]). History of renal transplantation Known carrier of the Human Leukocyte Antigen-B *58:01 allele. Patients diagnosed with tumor lysis syndrome or Lesch-Nyhan syndrome Patients who in the opinion of investigator are unable to perform the patients' tasks associated with the protocol or Presence of any condition which, places the patient at undue risk or potentially jeopardises the quality of the data to be generated History of stroke, myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft in the past 6 months Uncontrolled hypertension presenting with systolic blood pressure >180 mm Hg and/or diastolic blood pressure >100 mm Hg Diagnosed with heart failure and New York Heart Association Functional Classification Class IV at the time of randomisation QT interval corrected by the Fridericia formula >470 msec; patients diagnosed with long QT syndrome; patients with a family history of long QT syndrome. Subjects with severe hepatic impairment, as judged by the investigator, of Child-Pugh Class C (decompensated cirrhosis), or with major cirrhosis complications (eg, hepatorenal syndrome) Receiving cytotoxic or immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment Treated with any drug for hyperuricaemia in the 6 months preceding randomisation. Dose of ACEi, ARBs, fenofibrate, guaifenesin, or SGLT2 inhibitors changed within 4 weeks of randomisation or further dose titration expected after randomization
Facility Information:
Facility Name
Research Site
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35805
Country
United States
Facility Name
Research Site
City
Bakersfield
State/Province
California
ZIP/Postal Code
93309
Country
United States
Facility Name
Research Site
City
Canyon Country
State/Province
California
ZIP/Postal Code
91351
Country
United States
Facility Name
Research Site
City
Laguna Hills
State/Province
California
ZIP/Postal Code
92653
Country
United States
Facility Name
Research Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90807
Country
United States
Facility Name
Research Site
City
Northridge
State/Province
California
ZIP/Postal Code
91324
Country
United States
Facility Name
Research Site
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Research Site
City
Thousand Oaks
State/Province
California
ZIP/Postal Code
91360
Country
United States
Facility Name
Research Site
City
Vacaville
State/Province
California
ZIP/Postal Code
95687
Country
United States
Facility Name
Research Site
City
Victorville
State/Province
California
ZIP/Postal Code
92395
Country
United States
Facility Name
Research Site
City
Denver
State/Province
Colorado
ZIP/Postal Code
80230
Country
United States
Facility Name
Research Site
City
Bloomfield
State/Province
Connecticut
ZIP/Postal Code
06002
Country
United States
Facility Name
Research Site
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20037
Country
United States
Facility Name
Research Site
City
Altamonte Springs
State/Province
Florida
ZIP/Postal Code
32701
Country
United States
Facility Name
Research Site
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
Facility Name
Research Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32204
Country
United States
Facility Name
Research Site
City
Lauderdale Lakes
State/Province
Florida
ZIP/Postal Code
33313
Country
United States
Facility Name
Research Site
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33015
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33126-2956
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33165
Country
United States
Facility Name
Research Site
City
Ocala
State/Province
Florida
ZIP/Postal Code
34471
Country
United States
Facility Name
Research Site
City
Ocoee
State/Province
Florida
ZIP/Postal Code
34761
Country
United States
Facility Name
Research Site
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33026
Country
United States
Facility Name
Research Site
City
Port Charlotte
State/Province
Florida
ZIP/Postal Code
33952
Country
United States
Facility Name
Research Site
City
Lawrenceville
State/Province
Georgia
ZIP/Postal Code
30046
Country
United States
Facility Name
Research Site
City
Wauconda
State/Province
Illinois
ZIP/Postal Code
60084
Country
United States
Facility Name
Research Site
City
Paducah
State/Province
Kentucky
ZIP/Postal Code
42003
Country
United States
Facility Name
Research Site
City
Takoma Park
State/Province
Maryland
ZIP/Postal Code
20912
Country
United States
Facility Name
Research Site
City
Flint
State/Province
Michigan
ZIP/Postal Code
48504
Country
United States
Facility Name
Research Site
City
Flint
State/Province
Michigan
ZIP/Postal Code
48532
Country
United States
Facility Name
Research Site
City
Saint Clair Shores
State/Province
Michigan
ZIP/Postal Code
48081
Country
United States
Facility Name
Research Site
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55404
Country
United States
Facility Name
Research Site
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Research Site
City
Jamaica
State/Province
New York
ZIP/Postal Code
11432
Country
United States
Facility Name
Research Site
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28801
Country
United States
Facility Name
Research Site
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28803
Country
United States
Facility Name
Research Site
City
Rocky Mount
State/Province
North Carolina
ZIP/Postal Code
27804
Country
United States
Facility Name
Research Site
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Research Site
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Research Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Research Site
City
Orangeburg
State/Province
South Carolina
ZIP/Postal Code
29118
Country
United States
Facility Name
Research Site
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37923
Country
United States
Facility Name
Research Site
City
Arlington
State/Province
Texas
ZIP/Postal Code
76015
Country
United States
Facility Name
Research Site
City
El Paso
State/Province
Texas
ZIP/Postal Code
79935
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77004
Country
United States
Facility Name
Research Site
City
Lampasas
State/Province
Texas
ZIP/Postal Code
76550
Country
United States
Facility Name
Research Site
City
Lewisville
State/Province
Texas
ZIP/Postal Code
75057
Country
United States
Facility Name
Research Site
City
Pearland
State/Province
Texas
ZIP/Postal Code
77584
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78212
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
Research Site
City
Alexandria
State/Province
Virginia
ZIP/Postal Code
22304
Country
United States
Facility Name
Research Site
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
Research Site
City
Frydek
ZIP/Postal Code
738 01
Country
Czechia
Facility Name
Research Site
City
Praha 2
ZIP/Postal Code
128 08
Country
Czechia
Facility Name
Research Site
City
Praha 6
ZIP/Postal Code
160 00
Country
Czechia
Facility Name
Research Site
City
Slany
ZIP/Postal Code
274 01
Country
Czechia
Facility Name
Research Site
City
Třebíč
ZIP/Postal Code
674 01
Country
Czechia
Facility Name
Research Site
City
Annonay
ZIP/Postal Code
07103
Country
France
Facility Name
Research Site
City
Grenoble cedex 9
ZIP/Postal Code
38043
Country
France
Facility Name
Research Site
City
Marseille cedex 5
ZIP/Postal Code
13385
Country
France
Facility Name
Research Site
City
Paris
ZIP/Postal Code
75018
Country
France
Facility Name
Research Site
City
Paris
ZIP/Postal Code
75970
Country
France
Facility Name
Research Site
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
Research Site
City
Tours
ZIP/Postal Code
37000
Country
France
Facility Name
Research Site
City
Baja
ZIP/Postal Code
6500
Country
Hungary
Facility Name
Research Site
City
Balatonfured
ZIP/Postal Code
8230
Country
Hungary
Facility Name
Research Site
City
Budapest
ZIP/Postal Code
1033
Country
Hungary
Facility Name
Research Site
City
Budapest
ZIP/Postal Code
1036
Country
Hungary
Facility Name
Research Site
City
Debrecen
ZIP/Postal Code
4025
Country
Hungary
Facility Name
Research Site
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Research Site
City
Hatvan
ZIP/Postal Code
3000
Country
Hungary
Facility Name
Research Site
City
Kaposvár
ZIP/Postal Code
7400
Country
Hungary
Facility Name
Research Site
City
Nyíregyháza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
Research Site
City
Nyíregyháza
ZIP/Postal Code
4405
Country
Hungary
Facility Name
Research Site
City
Szeged
ZIP/Postal Code
6725
Country
Hungary
Facility Name
Research Site
City
Zalaegerszeg
ZIP/Postal Code
8900
Country
Hungary
Facility Name
Research Site
City
Afula
ZIP/Postal Code
1834111
Country
Israel
Facility Name
Research Site
City
Ashdod
ZIP/Postal Code
77000
Country
Israel
Facility Name
Research Site
City
Ashkelon
ZIP/Postal Code
78278
Country
Israel
Facility Name
Research Site
City
Beer Sheba
ZIP/Postal Code
8410101
Country
Israel
Facility Name
Research Site
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Facility Name
Research Site
City
Haifa
ZIP/Postal Code
34362
Country
Israel
Facility Name
Research Site
City
Haifa
ZIP/Postal Code
35152
Country
Israel
Facility Name
Research Site
City
Holon
ZIP/Postal Code
58100
Country
Israel
Facility Name
Research Site
City
Kfar Sava
ZIP/Postal Code
44281
Country
Israel
Facility Name
Research Site
City
Nahariya
ZIP/Postal Code
22100
Country
Israel
Facility Name
Research Site
City
Nazareth
ZIP/Postal Code
16100
Country
Israel
Facility Name
Research Site
City
Petach-Tikva
ZIP/Postal Code
49100
Country
Israel
Facility Name
Research Site
City
Ramat Gan
ZIP/Postal Code
52621
Country
Israel
Facility Name
Research Site
City
Rehovot
ZIP/Postal Code
7642001
Country
Israel
Facility Name
Research Site
City
Safed
ZIP/Postal Code
13100
Country
Israel
Facility Name
Research Site
City
Tel-Aviv
ZIP/Postal Code
61480
Country
Israel
Facility Name
Research Site
City
Tiberias
ZIP/Postal Code
15208
Country
Israel
Facility Name
Research Site
City
Genova
ZIP/Postal Code
16132
Country
Italy
Facility Name
Research Site
City
Milano
ZIP/Postal Code
20132
Country
Italy
Facility Name
Research Site
City
Parma
ZIP/Postal Code
43126
Country
Italy
Facility Name
Research Site
City
Pavia
ZIP/Postal Code
27100
Country
Italy
Facility Name
Research Site
City
Verona
ZIP/Postal Code
37124
Country
Italy
Facility Name
Research Site
City
Ciudad Madero
ZIP/Postal Code
89440
Country
Mexico
Facility Name
Research Site
City
Estado de Mexico
ZIP/Postal Code
54800
Country
Mexico
Facility Name
Research Site
City
Guadalajara
ZIP/Postal Code
44650
Country
Mexico
Facility Name
Research Site
City
Mexico
ZIP/Postal Code
03100
Country
Mexico
Facility Name
Research Site
City
Mexico
ZIP/Postal Code
06700
Country
Mexico
Facility Name
Research Site
City
Tijuana
ZIP/Postal Code
22500
Country
Mexico
Facility Name
Research Site
City
Veracruz
ZIP/Postal Code
91910
Country
Mexico
Facility Name
Research Site
City
Krakow
ZIP/Postal Code
31-559
Country
Poland
Facility Name
Research Site
City
Lodz
ZIP/Postal Code
90-302
Country
Poland
Facility Name
Research Site
City
Lublin
ZIP/Postal Code
20-538
Country
Poland
Facility Name
Research Site
City
Poznań
ZIP/Postal Code
61-655
Country
Poland
Facility Name
Research Site
City
Rzeszów
ZIP/Postal Code
35-055
Country
Poland
Facility Name
Research Site
City
Warszawa
ZIP/Postal Code
00-465
Country
Poland
Facility Name
Research Site
City
Wroclaw
ZIP/Postal Code
50-127
Country
Poland
Facility Name
Research Site
City
Bucuresti
ZIP/Postal Code
010192
Country
Romania
Facility Name
Research Site
City
Bucuresti
ZIP/Postal Code
010825
Country
Romania
Facility Name
Research Site
City
Bucuresti
ZIP/Postal Code
050538
Country
Romania
Facility Name
Research Site
City
Bucuresti
ZIP/Postal Code
40172
Country
Romania
Facility Name
Research Site
City
Deva
ZIP/Postal Code
330084
Country
Romania
Facility Name
Research Site
City
Ploiesti
ZIP/Postal Code
100342
Country
Romania
Facility Name
Research Site
City
Satu Mare
ZIP/Postal Code
440055
Country
Romania
Facility Name
Research Site
City
Timișoara
ZIP/Postal Code
300456
Country
Romania
Facility Name
Research Site
City
Bardejov
ZIP/Postal Code
085 01
Country
Slovakia
Facility Name
Research Site
City
Bratislava
ZIP/Postal Code
85101
Country
Slovakia
Facility Name
Research Site
City
Hlohovec
ZIP/Postal Code
920 01
Country
Slovakia
Facility Name
Research Site
City
Kosice
Country
Slovakia
Facility Name
Research Site
City
Kralovsky Chlmec
ZIP/Postal Code
077 01
Country
Slovakia
Facility Name
Research Site
City
Lucenec
ZIP/Postal Code
984 01
Country
Slovakia
Facility Name
Research Site
City
Puchov
ZIP/Postal Code
2001
Country
Slovakia
Facility Name
Research Site
City
Rimavska Sobota
ZIP/Postal Code
979 01
Country
Slovakia
Facility Name
Research Site
City
Svidnik
ZIP/Postal Code
08901
Country
Slovakia
Facility Name
Research Site
City
Benoni
ZIP/Postal Code
1501
Country
South Africa
Facility Name
Research Site
City
Cape Town
ZIP/Postal Code
1730
Country
South Africa
Facility Name
Research Site
City
Cape Town
ZIP/Postal Code
7505
Country
South Africa
Facility Name
Research Site
City
Cape Town
ZIP/Postal Code
7570
Country
South Africa
Facility Name
Research Site
City
Cape Town
ZIP/Postal Code
7925
Country
South Africa
Facility Name
Research Site
City
Durban
ZIP/Postal Code
4001
Country
South Africa
Facility Name
Research Site
City
Durban
ZIP/Postal Code
4092
Country
South Africa
Facility Name
Research Site
City
George
ZIP/Postal Code
6530
Country
South Africa
Facility Name
Research Site
City
Johannesburg
ZIP/Postal Code
2001
Country
South Africa
Facility Name
Research Site
City
Johannesburg
ZIP/Postal Code
2132
Country
South Africa
Facility Name
Research Site
City
Krugersdorp
ZIP/Postal Code
1739
Country
South Africa
Facility Name
Research Site
City
Lenasia
ZIP/Postal Code
1827
Country
South Africa
Facility Name
Research Site
City
Paarl
ZIP/Postal Code
7647
Country
South Africa
Facility Name
Research Site
City
Stanger
ZIP/Postal Code
4450
Country
South Africa
Facility Name
Research Site
City
Tshwane
ZIP/Postal Code
0084
Country
South Africa
Facility Name
Research Site
City
Worcester
ZIP/Postal Code
6850
Country
South Africa
Facility Name
Research Site
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Facility Name
Research Site
City
Alicante
ZIP/Postal Code
03550
Country
Spain
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
08023
Country
Spain
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Research Site
City
Ciudad Real
ZIP/Postal Code
13005
Country
Spain
Facility Name
Research Site
City
Cordoba
ZIP/Postal Code
14004
Country
Spain
Facility Name
Research Site
City
Girona
ZIP/Postal Code
17007
Country
Spain
Facility Name
Research Site
City
Granada
ZIP/Postal Code
18012
Country
Spain
Facility Name
Research Site
City
L'Hospitalet De Llobregat
ZIP/Postal Code
08907
Country
Spain
Facility Name
Research Site
City
Málaga
ZIP/Postal Code
29011
Country
Spain
Facility Name
Research Site
City
Palma de Mallorca
ZIP/Postal Code
7120
Country
Spain
Facility Name
Research Site
City
Puerto De Sagunto
ZIP/Postal Code
46520
Country
Spain
Facility Name
Research Site
City
Santander
ZIP/Postal Code
39010
Country
Spain
Facility Name
Research Site
City
Sevilla
ZIP/Postal Code
41071
Country
Spain
Facility Name
Research Site
City
Valencia
ZIP/Postal Code
46014
Country
Spain
Facility Name
Research Site
City
Valencia
ZIP/Postal Code
46017
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing URL
https://astrazenecagroup-dt.pharmacm.com/DT/Home
Citations:
PubMed Identifier
34383954
Citation
Heerspink HJL, Stack AG, Terkeltaub R, Greene TA, Inker LA, Bjursell M, Perl S, Rikte T, Erlandsson F, Perkovic V. Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. Nephrol Dial Transplant. 2022 Jul 26;37(8):1461-1471. doi: 10.1093/ndt/gfab237.
Results Reference
derived
Links:
URL
https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D5495C00002&attachmentIdentifier=40101669-5639-49e4-88e0-31ed4e294c1d&fileName=d5495c00002StudySynopsisRedacted.pdf&versionIdentifier=
Description
CSR

Learn more about this trial

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

We'll reach out to this number within 24 hrs